Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib vs Methotrexate in Moderate-to-Severe Plaque Psoriasis
NCT07915492Phase 4Active, not recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of deucravacitinib in plaque psoriasis (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoints: Psoriasis Area and Severity Index at 30 days, Pruritus Visual Analog Scale at 30 days and 1 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07915492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915492.